PriceTargets.com logo

Nanobiotix - NBTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 287.10%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.10 As of 12/20/2024 06:16 PM ET
▼ -0.18 (-5.49%)

This chart shows the closing price for NBTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nanobiotix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBTX

Analyst Price Target is $12.00
▲ +287.10% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nanobiotix in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 287.10% upside from the last price of $3.10.

This chart shows the closing price for NBTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Nanobiotix.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/28/2024GuggenheimInitiated CoverageBuy$12.00
4/26/2024HC WainwrightReiterated RatingBuy
12/8/2023Leerink PartnrsReiterated RatingOutperform
12/8/2023Leerink PartnersInitiated CoverageOutperform$11.00
12/22/2021UBS GroupDowngradeBuy ➝ Neutral
4/30/2021Kepler Capital MarketsReiterated RatingBuy
4/23/2021Kepler Capital MarketsReiterated RatingBuy
1/5/2021Evercore ISIInitiated CoverageOutperform
1/5/2021UBS GroupInitiated CoverageBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nanobiotix logo
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Read More

Today's Range

Now: $3.10
Low: $3.10
High: $3.39

50 Day Range

MA: $3.91
Low: $2.81
High: $4.96

52 Week Range

Now: $3.10
Low: $2.76
High: $8.96

Volume

219,334 shs

Average Volume

21,117 shs

Market Capitalization

$146.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Nanobiotix?

The following Wall Street sell-side analysts have issued research reports on Nanobiotix in the last year: Guggenheim, and HC Wainwright.
View the latest analyst ratings for NBTX.

What is the current price target for Nanobiotix?

0 Wall Street analysts have set twelve-month price targets for Nanobiotix in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 287.1%. Guggenheim has the highest price target set, predicting NBTX will reach $12.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $12.00 for Nanobiotix in the next year.
View the latest price targets for NBTX.

What is the current consensus analyst rating for Nanobiotix?

Nanobiotix currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBTX will outperform the market and that investors should add to their positions of Nanobiotix.
View the latest ratings for NBTX.

What other companies compete with Nanobiotix?

Other companies that are similar to Nanobiotix include Terns Pharmaceuticals, ORIC Pharmaceuticals, VectivBio, Phathom Pharmaceuticals and Tourmaline Bio. Learn More about companies similar to Nanobiotix.

How do I contact Nanobiotix's investor relations team?

The company's listed phone number is 33-1-40-26-04-70. The official website for Nanobiotix is www.nanobiotix.com. Learn More about contacing Nanobiotix investor relations.